|Dr. Mitchell S. Steiner F.A.C.S., M.D., F.A.C.S||Chairman, Pres & CEO||874.6k||N/A||1961|
|Dr. Harry Fisch||Vice Chairman & Chief Corp. Officer||465.02k||N/A||1959|
|Ms. Michele Greco||CFO & Chief Admin. Officer||443.72k||N/A||1959|
|Dr. K. Gary Barnette Ph.D.||Chief Scientific Officer||507.01k||N/A||1968|
|Mr. Samuel Fisch||Director of Investor Relations||N/A||N/A||N/A|
|Mr. Michael J. Purvis||VP, Gen. Counsel & Corp. Strategy||N/A||N/A||N/A|
|Mr. Kevin J. Gilbert CPA, J.D.||Exec. VP of Corp. Devel.||N/A||N/A||N/A|
|Dr. Robert H. Getzenberg||Exec. VP for Medical Affairs||N/A||N/A||N/A|
|Mr. Phillip Kuhn||Exec. VP of Strategy & Commercial||N/A||N/A||N/A|
|Dr. Domingo Rodriguez||Exec. VP of Clinical Operations||N/A||N/A||1962|
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include VERU-111, an oral chemical entity that is being evaluated in open label Phase 1b and Phase 2 clinical trials in men with metastatic castration and androgen receptor targeting agent resistant prostate cancer, as well as being evaluated in a Phase 2 clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome; and for the treatment of taxane resistant metastatic triple negative breast cancer. Its drug candidates also comprise VERU-100, a gonadotropin-releasing hormone antagonist peptide formulation to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer; and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist to treat hot flashes, a common side effect caused by ADT in men with advanced prostate cancer. In addition, the company's drug candidates include Enobosarm, an oral selective androgen receptor agonist that targets the androgen receptor positive, estrogen receptor positive, and human epidermal growth factor receptor 2 metastatic breast cancer without the unwanted virilizing side effects. Further, it is advancing a new drug formulation in its specialty pharmaceutical pipeline addressing unmet medical needs in urology, such as Tadalafil and Finasteride Combination. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. is headquartered in Miami, Florida.
Veru Inc.’s ISS Governance QualityScore as of April 30, 2021 is 5. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 4; Compensation: 6.